Trans-Pacific AusperBio has drawn $120M to advance an antisense oligonucleotide therapy (ASO) targeting chronic hepatitis B. The financing is positioned to support clinical development and commercialization preparation for an HBV program designed to modulate a viral RNA pathway rather than relying solely on polymerase inhibition. For biotech, the funding matters because chronic HBV remains a durable market with high unmet need around functional cure. Large late-stage investment can accelerate trial timelines, manufacturability, and evidence generation required for broader payer and guideline adoption. The deal also reflects ongoing capital allocation toward nucleic-acid medicines, with HBV continuing to be a strategic therapeutic arena for next-generation RNA-targeted approaches.